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Abstract: Pharmacological treatment and several drugs of abuse have been associated with ischemic heart disease (IHD) 
and cerebrovascular diseases (CVD). However, there is a paucity of data on the independent risk
 of vascular disease (VD) 
associated with pharmacological treatment and no controlled trials
 demonstrating a reduction in risk with abstinence.  
Information about IHD and CVD-related drug abuse is mainly limited
 to epidemiological studies focused on urban popu-
lations. The potential link between some pharmacological treatments (estrogen, some oncologic drugs and some atypical 
antipsychotics) and cerebrovascular adverse events was analyzed, but disagreement about an association persists. Drugs
 of 
abuse, including cocaine, amphetamines and heroin, have
 been associated with an increased vascular risk.  
These drugs
 can cause abrupt changes in blood pressure, vasculitic-type
 changes, lead to embolization caused by infective 
endocarditis, and hemostatic and hematologic abnormalities that can result in increased blood viscosity and platelet ag-
gregation. Long-term treatment strategies based on medication, psychological support, and outreach programs play an im-
portant role in treatment of drug dependency.  
In these last years public interest in risk factors for VD has been constantly increasing and the successful identification 
and management of pharmacological treatment and drug abuse can be challenging. One of the major public health issues 
for the future will be to focus more on new vascular risk factor recognition and management.  
The objective of this chapter is to review the relevance of IHD and CVD associated with various pharmacological treat-
ments and drug abuse with focusing on ischemic disease.  
This chapter reports the clinical evidence of this association and analyzes the experimental role of new drugs as a growing 
risk factor of VD with the hypothetical new association. In conclusion, in this chapter great attention is paid to evaluating 
the scientific and real evidence of cerebrovascular effect and drug use and abuse so as to identify a new groups of “modi-
fiable” risk factors.  
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INTRODUCTION 
  VD is the major cause of death and disability worldwide. 
Strategies to reduce the incidence of VD include prevention 
of first-ever and recurrent VD. One of the main strategies of 
stroke and IDH prevention is the “high risk” approach which 
aims to reduce VD by identifying individuals at high vascu-
lar risk and lowering their risk by means of optimal medical 
therapies. VD prevention is a crucial issue and consists of an 
optimal management of vascular risk factors.  
  Most patients with recurrent VD had multiple risk factors 
identified at the time of their first stroke or/and IDH, but 
most of these risk factors were either undertreated or un-
treated. A smaller number of patients had newly identified 
vascular risk factors at admission. Epidemiological studies 
have advanced our understanding of new vascular risk fac-
tors and clinical trials have demonstrated effective interven-
tions to decrease VD risk by modifying vascular risk factors.  
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The categories are expanding and include those related to 
infection, inflammation, sleep disorders, haemostasis, nutri-
tion, endocrine, one's individual genotype, drugs of abuse 
and specific pharmacological treatment; these are non-
traditional risk factors for VD in rapid expansion. Many of 
the promising factors lack large randomized prospective 
population studies confirming direct cause and effect.  
  The complexity of the pathophysiology of this disease 
remains a challenge.  
EXPERIMENTAL AND CLINICAL EVIDENCE OF 
PHARMACOLOGICAL VASCULAR RISK  
Pathophysiology  
  The aim of pathophysiology in VD is on the blood and/or 
endothelium disease. Vascular dysfunction underlies the 
pathophysiology of a wide range of diseases, including athe-
rosclerosis, mechanical stress, smoke exposure, hypercholes-
terolemia, hyperhomocysteinemia and chronic infection (di-
rect or indirect), diabetes and arthritis. The endothelium 
plays an important role in cardio and cerebrovascular ho-
meostasis, either through the vascular tonus and its regula-
tion, or through coagulation and the inflammatory response Clinical Pharmacology and Vascular Risk  The Open Neurology Journal, 2010, Volume 4    65 
[1]. Endothelial dysfunction is implicated in the genesis of 
atherosclerosis and other chronic disorders, such as diabetes 
mellitus and hypertension. Abnormalities of the vascular 
endothelium contribute to all stages of atherosclerosis from 
lesion development to clinical IDH events. A variety of 
pharmacological and behavioural interventions have been 
shown to reverse endothelial dysfunction in patients with 
IDH. A large number of epidemiological studies suggest that 
dietary factors, including increased intake of flavonoid-
containing foods and beverages, reduce cardiovascular risk, 
and recent studies have shown that such beverages have fa-
vourable effects on endothelial function [2]. Angiogenic 
function is progressively impaired with increasing age and, 
therefore, has been linked to the increased risk of many of 
these diseases among older people.  
  Blood levels of inflammatory markers (e.g., C-reactive 
protein CPR, serum amyloid A, fibrinogen, plasma viscosity, 
erythrocyte sedimentation rate, leukocyte count and low se-
rum albumin) have been associated with vascular risk factors 
and with prevalent and incident atherothrombotic cardiovas-
cular disease (coronary heart disease, stroke and peripheral 
arterial disease). More recently, cytokines (e.g., interleukin-
6) and soluble adhesion molecules (e.g., intercellular adhe-
sion molecule-1, vascular cell adhesion molecule-1) have 
been associated with both risk factors and disease [3]. Raised 
plasma fibrinogen levels are associated with an increased 
risk of vascular events. This may be mediated by adverse 
effects of fibrinogen on plasma viscosity, coagulation, plate-
let activity, inflammation and atherogenesis [4]. However, 
there is as yet no drug that specifically lowers plasma fi-
brinogen levels on a long-term basis. Some trials have dem-
onstrated that lowering plasma fibrinogen levels will result 
in a decreased risk of vascular events [3]. However, such a 
trial may never happen unless a specific agent is discovered 
or designed. Several drugs that are used in VD prevention 
(e.g., lipid lowering agents and antihypertensives) may influ-
ence plasma fibrinogen levels. Whether such an additional 
effect accounts for variations in the benefit resulting from 
the use of different drugs within the same class remains to be 
established. The debate continues as to whether fibrinogen is 
just a marker of vascular risk or whether lowering its circu-
lating levels will result in a significant decrease in clinically 
relevant endpoints. Whatever the case, the measurement of 
plasma fibrinogen levels is likely to provide a more compre-
hensive estimation of risk.  
  Unique drug targets have already been identified in some 
of these emerging vascular risk factors (Table 1).  
Table 1.  Clinical Pharmacological Vascular Risk Factors 
 
Some Pharmacological  
Treatment 
Several Drugs of Abuse 
 sex hormone therapy   pharmacological drugs 
 oral contraceptive use   cocaine, amphetamines and heroin 
 antipsychotic drugs   
 thiazolidinediones   
 immunomodulatory drugs   
 antiepileptic drugs   
 COX-inhibitors   
 HMG-CoA reductase inhibitors   
Sex hormone Therapy  
  Menopause is a risk factor for VD because estrogen 
withdrawal has a detrimental effect on cardiovascular func-
tion and metabolism. Now there is evidence of an association 
between endothelial dysfunction and reduced endogenous 
production of estrogens after natural or surgical menopause 
or premature ovarian failure in women with or without coro-
nary arterial disease [5]. The menopause compounds many 
traditional VD risk factors, including changes in body fat 
distribution from a gynoid to an android pattern, reduced 
glucose tolerance, abnormal plasma lipids, increased blood 
pressure, increased sympathetic tone, endothelial dysfunc-
tion and vascular inflammation.  
  The actions of endogenous estrogens on the cardiovascu-
lar system can be mediated directly on the vessels or indi-
rectly through the modulation of cardiovascular risk factors, 
as well as on the lipid profile (reduction of total cholesterol 
and LDL, increase in HDL), as already described more than 
20 years ago. More recently, studies have also demonstrated 
an antioxidant effect by estrogen, reducing LDL oxidation in 
vivo and in vitro [6]. The direct effects of estrogen on the 
vascular system which modulate the vascular tonus comprise 
I) acute vasodilatation, increasing the synthesis and bioactiv-
ity of nitric oxide [7], II) long-term modulation of vascular 
tonus, regulating the production of prostaglandins and ex-
pression of eNOS and the endothelin gene [8], III) inhibition 
of endothelin-induced vasoconstriction [9], and IV) inhibi-
tion of sympathetic activity [8]. In addition to these actions 
on the vascular tonus, estrogen exerts an antiproliferative 
action on the vascular smooth layer [10]. It also appears to 
have a major role in vascular remodeling, inhibiting the pro-
liferation of the inner layer after injury [11] and increasing 
the expression of contractile proteins in the myocardium 
[12]. Despite repeated evidence of estrogen-related neuro-
protection, large population-based studies in postmenopausal 
women receiving estrogen replacement did not demonstrate 
the expected neuroprotection.  
  On the other hand, androgen and sex hormone-binding 
globulin levels have been associated with risk of cardiovas-
cular disease in pre- and postmenopausal women [13]. An 
increase in circulating androgens appears to be associated 
with insulin resistance and a predictor of diabetes mellitus 
[14]. In previous studies a positive association, independent 
of obesity, was demonstrated between testosterone levels and 
hyperinsulinemia in postmenopausal women with no clinical 
evidence of VD [15]. In some tissues, such as the liver, es-
trogen can mediate both beneficial (expression of genes of 
apoproteins that improve the lipid profile) and adverse ef-
fects (increase in the expression of procoagulant factors and 
decrease of fibrinolytic factors) [4].  
  The pharmacological use of estrogen exerts influence on 
the circulating levels of markers of vascular tonus, and in-
flammation, as well as prothrombotic, and fibrinolytic mark-
ers, but the impact of these changes on the atherosclerotic 
disease is still uncertain. Clinical and animal studies suggest 
multiple cardiovascular effects of selective estrogen receptor 
modulators. For example, raloxifene lowers serum levels of 
cholesterol and homocysteine, attenuates oxidation of low-
density lipoprotein, inhibits endothelial-leucocyte interac-
tion, improves endothelial function and reduces vascular 
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raloxifene and tamoxifen are capable of acting directly on 
both endothelial cells and the underlying vascular smooth 
muscle cells and cause a multitude of favourable modifica-
tions of the vascular wall, which jointly contribute to im-
proved local blood flow.  
  Observational studies and randomized clinical trials sug-
gest that hormone replacement therapy (HRT) started soon 
after the menopause may confer cardiovascular benefit. In 
contrast to other synthetic progestogens used in continuous 
combined HRTs, the unique progestogen drospirenone has 
antialdosterone properties. Drospirenone can therefore coun-
teract the water- and sodium-retaining effects of the estrogen 
component of HRT via  the renin-angiotensin-aldosterone 
system, which may otherwise result in weight gain and 
raised blood pressure. As a continuous combined HRT with 
17beta-estradiol, drospirenone has been shown to signifi-
cantly reduce blood pressure in postmenopausal women with 
elevated blood pressure, but not in normotensive women. 
Therefore, in addition to relieving climacteric symptoms, 
drospirenone/17beta-estradiol may offer further benefits in 
postmenopausal women, such as improved CVD risk profile 
[16].  
  Estrogen deficiency causes progressive reduction in en-
dothelial function. Despite the benefits of HRT evident in 
earlier epidemiological studies, recent randomized trials of 
HRT for the prevention of heart disease found no overall 
benefit. Instead, HRT users had higher incidences of stroke 
and heart attack. Although experimental data and results of 
observational studies suggest that HRT was associated with a 
reduction in the risk of heart disease, the results for stroke 
have been far less clear. Several recent randomized secon-
dary prevention studies have found that HRT is not protec-
tive against the risk of coronary heart disease, stroke or pro-
gression of atherosclerosis. Moreover, an increased risk of 
stroke and first coronary event with hormone therapy has 
been found in low-risk healthy post menopausal women. In 
the light of these findings, although the absolute risk of vas-
cular event associated with HRT is low, most organizations 
recommend caution in using HRT and finally in postmeno-
pausal women, treatment of arterial hypertension and glu-
cose intolerance should be priorities. 
Oral Contraceptive Use  
  The most frequent major adverse effect of hormonal con-
traception is an increased risk of VD. The effect on the risk 
of venous thromboembolism, CVD and IHD differs and is 
strongly influenced by smoking and the presence of other 
cardiovascular risks factors, such as hypertension and diabe-
tes mellitus. The incidence of each disease rises with age and 
there are differences in risk among hormonal contraceptive 
preparations.  
  Mortality rates for cardiovascular diseases are very low 
in women of reproductive age. IDH mortality rates rise from 
< 0.4 per 100,000 woman-years at age 15-24 years to the 
range 2 to 7 per 100,000 woman-years at age 35-44 years. 
Stroke mortality rates similarly rise steeply with age and are 
between 3 and 5 times higher than those for IDH. Venous 
thromboembolism mortality rates rise less steeply with age 
and are approximately one-tenth the IDH mortality rates at 
age 35-44 years. The adverse effect of oral contraceptives 
(OC) on the risk of venous thromboembolism is the most 
important contributor to the total number of cardiovascular 
cases attributable to OC use. The increased risk of stroke and 
IDH dominate the patterns of mortality in OC users and 
smokers. The additional risks attributable to smoking are 
greater than the additional risks attributable to OC use. The 
risk attributable to OC use in women < 35 years of age is 
small, even if they smoke, but there are substantially in-
creased risks in older women who both smoke and use OC. 
The additional mortality attributable to OC use can be re-
duced by screening users, as this results in lower relative 
risks of ischemic stroke and IDH. Differences between OC 
types in the relative risk of venous thromboembolism con-
tribute little to the total cardiovascular mortality associated 
with OC use, even though the total number of cardiovascular 
events is increased. A potential reduction in the risk of IDH 
with desogestrel and gestodene compared with levonorg-
estrel-containing OC would have little difference on overall 
mortality rates in women in their 20s and 30s, but may result 
in a net reduction in OC-attributable mortality in women 
aged 40-44 years who smoke. An overall quantification of 
the risks for different types of oral contraceptive users is 
necessary for an informed choice of contraceptive method, 
and any assessment of the balance of cardiovascular risks is 
complex. The model provides a tool to assess, at the level of 
the individual, the risks associated with use of different OC 
according to personal circumstances. It is important to con-
sider the user's age and smoking status when determining 
OC attributable risks (17). Estrogen plus progestin was asso-
ciated with doubling the risk of venous thrombosis. Estrogen 
plus progestin therapy increased the risks associated with 
age, overweight or obesity, and factor V Leiden (18).  
  Much of the perceived increased stroke risk associated 
with
 the use of OCs is based on early studies with high-dose 
preparations
 (ie, first-generation OCs containing >50 g of 
estradiol) [19]. The majority of studies of later-generation 
OCs containing lower
 doses of estrogens did not find an in-
creased risk of stroke [20]. However, at least 1 study re-
ported an increased risk of stroke
 in women using first-, sec-
ond-, or third-generation OCs [21].
 Meta-analyses have also 
been conflicting [22], and the reasons
 for the discrepancy are 
not certain. Fewer data are available
 on the association be-
tween OC use and hemorrhagic stroke. The
  reported risks 
appear lower than for ischemic stroke [23],
  except among 
older women in whom the risk of hemorrhagic stroke
  is 
greatest  [24]. Few studies have examined the association
 
between the use of OCs and less common stroke mecha-
nisms. One
  exception is cerebral venous thrombosis, for 
which there are
  data to suggest an association, especially 
among women with
 congenital thrombophilias such as factor 
V Leiden or a prothrombin
 gene mutation [25].
  
The absolute increase in stroke risk with low-dose OCs, if 
one
 exists, is small. Estimates of the incidence of ischemic
 
stroke in young women range from 0.9 to ~ ~10 per 100,000 
[26]. Using the highest part of this range, even if the risk of 
stroke
 is increased by as much as 30% (ie, 3 per 100,000), 
the excess
 number of strokes associated with OC medication 
remains several-fold
 lower than the mortality rate for preg-
nancy in the United States
 (9 per 100,000 live births) [27].
 
Some groups of women appear to be at higher risk for stroke
 
associated with OC use. Women who are >35 years of age, 
smoke
  cigarettes, are hypertensive, are diabetic, have mi-
graines,
 or have had prior thromboembolic events (especially Clinical Pharmacology and Vascular Risk  The Open Neurology Journal, 2010, Volume 4    67 
if while
 on OCs) may be at increased stroke risk if they use 
OCs. Some
  data suggest that the total stroke risk may be 
more than additive
 for combinations of smoking, migraine 
with aura, and age >35
 years, but the issue remains unsettled 
for low-dose OCs [28].  
  The risk of stroke associated with OC use is low.
 Certain 
women, particularly those who have had a prior thrombotic
 
event, may be at higher risk. Estimates are primarily based
 
on epidemiological studies. The incremental risk of stroke 
associated with use of low-dose
 OCs in women without addi-
tional risk factors, if one exists,
 appears low [28]. It is sug-
gested
  that OCs be discouraged in women with additional 
risk factors
 (eg, cigarette smoking or prior thromboembolic 
events) [29].  For those who elect to assume
  the increased 
risk, aggressive therapy of stroke risk factors
 may be useful.  
Antipsychotic Drugs  
  A variety of behavioural disturbances such as physical 
aggression, agitation, hallucinations and wandering com-
monly accompany dementia. The term behavioural and psy-
chological symptoms of dementia-BPSD-describes this spec-
trum of non-cognitive manifestations of dementia [30]. The 
presence of BPSD can decrease quality of life for patients 
and caregivers, and increases the likelihood of the patient 
being placed in an institution [31]. Treatment of BPSD is 
challenging. A variety of non-pharmacological and pharma-
cological approaches have been assessed [32]. Atypical an-
tipsychotics are often prescribed to manage BPSD. Although 
such prescriptions represent off-label prescribing, this prac-
tise is widely endorsed because atypical antipsychotics are 
among the best studied treatments for BPSD and there is a 
perception that they have fewer adverse effects than typical 
antipsychotics [33].  
  In April 2005, the U.S. Food and Drug Administration 
(FDA) issued a public health advisory that the use of atypical 
antipsychotics to treat elderly patients with dementia was 
associated with an increased risk for death compared with 
placebo [34]. In June 2005, Health Canada issued a similar 
warning and additional data. These warnings stem from re-
views of short-term randomized, controlled trials (RCTs) 
that involve the atypical agents risperidone, olanzapine, 
quetiapine, and aripiprazole. The mortality rate was ap-
proximately 1.6 to 1.7 times higher than with placebo and 
was greater with antipsychotics than with placebo in 15 of 
the 17 trials reviewed by the U.S. FDA [35]. The warnings 
extend to all currently available atypical antipsychotics. 
Other publications have provided support for these warnings 
and have raised further safety concerns about older conven-
tional antipsychotics [36-38]. In a recent population-based, 
retrospective cohort study on older adults with dementia who 
were followed between 1 April 1997 and 31 March 2003, 
Gill [39] conclude that the use of atypical antipsychotics is 
associated with a small but significant increase in mortality 
among older adults with dementia. In addition, the risk for 
death associated with antipsychotics is apparent after as little 
as 1 month of use and may persist for 6 months. Finally, 
these data provide independent confirmation of reports that 
conventional antipsychotics confers an even greater risk for 
death than does use of atypical antipsychotics [37,40].  
  The potential causes of death associated with antipsy-
chotic use merit consideration. There was no available in-
formation on the proximate causes of death for all patients 
[41]. Nonetheless, several plausible mechanisms can be pro-
posed. First, antipsychotics may prolong the QT interval, 
predisposing patients to arrhythmias and sudden cardiac 
death [42]. Second, sedation and accelerated cognitive de-
cline brought on by exposure to antipsychotics may increase 
the risk for aspiration syndromes and choking [43]. Aspira-
tion pneumonia is an important cause of death among people 
with dementia [44]. Third, several studies have found a link 
between atypical antipsychotic use and venous thromboem-
bolism [45]; therefore, pulmonary embolism may be an un-
derrecognized cause of sudden death in these patients. 
Fourth, a risk for cerebrovascular events may be associated 
with antipsychotic use (Table 2).  
  If atypical agents do contribute to the risk of stroke, how-
ever, a plausible biological rationale must exist. The risk 
seems to develop quickly (6-12 weeks in clinical trials), and 
thus it seems unlikely that the risk is mediated through drug 
effects on risk factors such as glucose or lipid metabolism. 
The metabolic syndrome is highly prevalent in US schizo-
phrenia patients and represents an enormous source of car-
diovascular risk, especially for women [46]. Similarly, drug 
induced atrial fibrillation would be an unlikely explanation 
for such a rapid increase in the risk of cerebrovascular ad-
verse events. Potential mechanisms for cerebrovascular 
events related to atypical antipsychotics might include or-
thostatic hypotension in patients with pre-existing CVD, 
which might lead to “watershed” strokes [47] and antipsy-
chotic induced hyperprolactinaemia, which might promote 
platelet aggregation [48]. Others, however, have reported 
that risperidone may inhibit platelet aggregation (through 
serotonin receptor antagonism), rather than promote it [49]. 
Some observational data have shown that antipsychotics 
might be associated with an increased risk of venous throm-
boembolic disease [50]; arterial thrombosis such as stroke, 
however, shares few risk factors with venous thrombosis. A 
clear biological rationale has not yet been identified for an 
increased risk of stroke associated with use of atypical antip-
sychotics. The collection of data on “cerebrovascular adverse 
events” may have been influenced by patients’ receipt of 
active drug therapy or placebo in the clinical trials. For ex-
Table 2.  Potential Causes of Death Associated with Antipsychotic Use 
 
Antipsychotic use: directly action  Antipsychotic use: indirectly action  
prolong QT interval  sedation and cognitive decline  
arhytmias 
thrombosis and thromboembolism 
sedation and aspiration syndrome  
(pneumonia)  
orthostatic hypotension   
hyperprolactinaemia  68     The Open Neurology Journal, 2010, Volume 4  Silvestrelli et al. 
ample, it is possible that patients given antipsychotic treat-
ment with relief of psychoses might report more symptoms 
than patients given placebo [47].  
  In a recent population based retrospective cohort study 
Gill [51] identified 32,710 older adults with dementia 
(17,845 dispensed atypical antipsychotics and 14,865 dis-
pensed typical antipsychotics). In this population based co-
hort, older adults with BPSD who received atypical antipsy-
chotic drugs seem to have a similar risk of admission to hos-
pital for ischemic stroke as those receiving typical antipsy-
chotic drugs. They conclude that patients dispensed two 
more consecutive prescriptions (chronic users) of atypical 
antipsychotics were not at increased risk of stroke compared 
with chronic users of typical antipsychotics. Finally, the risk 
of stroke in the subgroup of patients was not significantly 
different between those receiving atypical antipsychotics and 
those receiving typical antipsychotics (adjusted hazard ratio 
0.98, 95% confidence interval 0.65 to 1.47).  
  Several investigators found no association between use of 
atypical antipsychotics and cerebrovascular events [52, 53]. 
In addition, recent data from a trial evaluating quetiapine for 
BPSD showed no increased risk of cerebrovascular adverse 
events compared with placebo.  
  Studies have shown that some patients receiving antipsy-
chotics can be successfully weaned from these medications 
when monitored closely [54]. Antipsychotic therapies should 
not be initiated if effective non-drug treatments are available 
or if symptoms are unlikely to respond to antipsychotic 
treatment (for example, repetitive vocalizations or wander-
ing).  
  These findings highlight the need to carefully balance 
potential risks and benefits when considering antipsychotic 
treatment for older adults with dementia and emphasize the 
need to limit use of these drugs to situations in which non-
pharmacologic measures have provided an inadequate re-
sponse.  
Thiazolidinediones  
  Thiazolidinediones significantly reduce fasting plasma 
glucose and HbA (1c). These effects are due to improved 
insulin sensitivity by activating the nuclear PPAR-gamma 
(peroxisomal proliferator-activated receptors-gamma) and 
affection of different intracellular functions. Many studies 
and meta-analyses about thiazolidinediones analysed a sig-
nificant cardiovascular risk associated with rosiglitazone 
therapy. Therefore clinicians have been left uncertain as to 
whether rosiglitazone should still be considered for the treat-
ment of type-2-diabetes. An important side-effect of 
thiazolidinediones is fluid retention and edema. Therefore, 
heart failure NYHA I-IV is a contraindication for treatment 
with thiazolidinediones. Pioglitazone shows favourable 
changes in lipid parameters like decrease of serum-
triglycerides and increase of HDL-cholesterol, while rosigli-
tazone temporarily increases LDL-cholesterol. In patients 
with type-2-diabetes mellitus and a high cardiovascular risk 
the PROactive study did not show a significant effect on the 
primary endpoint but significantly reduced the predefined 
secondary combined endpoint of total mortality, nonfatal 
myocardial infarction and stroke. Conversely, recently pub-
lished meta-analyses suggested an increased cardiovascular 
risk and IDH rate associated with rosiglitazone therapy [55]. 
Treatment with rosiglitazone should be reconsidered because 
of a potential cardiovascular risk. In high risk patients with-
out heart failure pioglitazone may be favoured for treatment 
of type 2 diabetes mellitus.  
Immunomodulatory Drugs  
  Molecular and cellular immune activities have a funda-
mental role in all stages of the atherosclerotic process and in 
the pathogenesis of VD. Recent studies have demonstrated 
how chronic infections can support a local and systemic 
chronic inflammation, leading to the atherosclerotic process 
[56, 57]. The pathogenic link between infection and VD is 
not completely defined. Some therapeutic strategies, able to 
influence the persistence of the infections or to modify the 
inflammatory process, could be useful in primary and secon-
dary vascular disease prevention and in modifying the acute 
event outcome.  
  Premature coronary heart disease has emerged as a major 
cause of morbidity and mortality in systemic autoimmune 
diseases. Recent epidemiologic and pathogenesis studies 
have suggested a great deal in common between the patho-
genesis of prototypic autoimmune disease such as rheuma-
toid arthritis and systemic lupus erythematosus and that of 
atherosclerosis. Some of the most remarkable data in support 
of a link between autoimmunity and atherosclerosis comes 
from epidemiological studies of patients with autoimmune 
disorders (rheumatoid arthritis and systemic lupus erythema-
tosus). Many epidemiologic observations have linked sys-
temic inflammation with the cardiovascular events in auto-
immune disease such as rheumatoid arthritis and systemic 
lupus erythematosus [58]. Systemic levels of soluble in-
flammatory mediators such as CRP have been associated 
with cardiovascular risk in the general population. CRP, or 
more specifically high sensitivity-hsCRP, is a marker of sys-
temic inflammation that has been identified as a valid bio-
marker of cardiovascular risk. Furthermore, the immuno-
modulatory and anti-inflammatory actions of statins may 
affect their utility in the context of chronic inflammatory 
autoimmune disease. Thus, effective control or dampening 
of inflammation, with such agents should be included in the 
therapeutic armamentarium of autoimmune diseases with the 
aim of protecting against cardiovascular disease [59].  
Antiepileptic Drugs  
  There is no evidence in literature about the risk of stroke 
and use of antiepileptic drugs (AED), but in clinical practice 
an association was found between use of antiepileptic drugs 
and cerebrovascular events. On the other hand stroke is the 
leading cause of symptomatic epilepsy in adults, accounting 
for up to one-third of newly diagnosed seizures among the 
elderly. About 3% to 5% of stroke patients will suffer a re-
mote seizure, 54% to 66% of whom will develop epilepsy. 
Thus far, the optimal timing and type of antiepileptic treat-
ment for patients with post-stroke seizure and epilepsy have 
not been specifically assessed. Although several studies sug-
gest that seizures alter the functional recovery after a stroke, 
it remains difficult to determine whether or not the occur-
rence of a second seizure in an untreated stroke patient might 
hamper the overall outcome. The decision to initiate AED 
treatment after a first or a second post-stroke seizure should 
therefore be individualized, primarily based on the functional 
impact of the first seizure episode and the patient's prefer-Clinical Pharmacology and Vascular Risk  The Open Neurology Journal, 2010, Volume 4    69 
ence. Several converging findings suggest that the majority 
of first-generation AEDs, particularly phenytoin, are not the 
most appropriate choice in stroke patients because of their 
potential harmful impact on functional recovery and bone 
health, their suboptimal pharmacokinetic profile and interac-
tion with anticoagulants or salicylates in modifying thera-
peutic efficacy in secondary prevention, their greater likeli-
hood of being poorly tolerated, and the lack of level A evi-
dence regarding their specific use in elderly patients. Among 
the new-generation AEDs that do not interact with antico-
agulants, antiplatelet agents, or bone health, lamotrigine and 
gabapentine are the only two drugs that proved to be more 
effective than immediate-release carbamazepine in elderly 
patients, providing level A evidence for their use in this indi-
cation. In addition, gabapentin remains the only drug that has 
been specifically evaluated in stroke patients, demonstrating 
a high rate of long-term seizure freedom. At present, low-
dose lamotrigine or gabapentin appear to represent the opti-
mal first-line therapy for post-stroke seizure and epilepsy in 
elderly patients or in younger patients requiring anticoagu-
lants. However, low-dose extended-release carbamazepine 
might be a reasonable and less expensive option in patients 
with appropriate bone health who do not require anticoagula-
tion [60]. 
COX-Inhibitors  
  The development of drugs that selectively inhibit cy-
clooxygenase-2 (COX-2) demonstrates translational research 
from bench to bedside based on underlying knowledge of 
micro-cellular structure and function. However, theoretical 
concerns about potentially prothrombotic effects of selective 
COX-2 inhibitors coupled with observations of increased 
cardiovascular risk have produced significant consternation 
and lead to the withdrawal of two of these agents from the 
market. A number of questions remain unanswered. It ap-
pears clear that both selective and non-selective COX inhibi-
tors are associated with increases in blood pressure. In addi-
tion, blood pressure is often increased after starting non-
steroidal therapy, and we know that even small increases in 
blood pressure in subjects with pre-existing vascular disease 
are associated with substantial increases in the risk of car-
diovascular morbidity. Given this line of reasoning, one 
might hypothesize that the observed increases in the risk of 
cardiovascular events associated with COX-inhibitors are 
largely due to increases in blood pressure in populations of 
subjects who are already at high risk. But can we generalize 
that the adverse cardiovascular effects observed for ro-
fecoxib and valdecoxib are sufficient to indict the entire 
class of COX-2 inhibitors, or is this not a class effect, but 
dependent upon the degree of COX-2 selectivity? In either 
case, it seems prudent to recommend that subjects who are at 
higher risk for a cardiovascular event and receiving a COX-
inhibitor should also be treated with low dose ASA with 
close follow up of blood pressure and efficacious use of anti-
hypertensive medications. Finally, modest dietary salt re-
striction may help lessen the effects of COX-inhibitors on 
blood pressure [61].  
HMG-CoA Reductase Inhibitors  
  Endothelial dysfunction has been shown to be a prognos-
tic factor for IDH and improvement of endothelial dysfunc-
tion prevents cardiovascular event presentation. Endothelial 
dysfunction is associated to a reduced nitric oxide (NO) bio-
activity, as a result of the impairment of NO synthe-
sis/release by the endothelial NO synthase (eNOS) or by 
inactivation of NO. Endothelial dysfunction measurements 
are valuable surrogate markers to assess the effectiveness of 
interventions addressed to prevent or treat ICHD. Dysli-
pemia and other cardiovascular risk factors promote endothe-
lial dysfunction and life style changes and pharmacological 
treatment, particularly HMG-CoA reductase inhibitors (stat-
ins), have shown early improvement of endothelial-
dependent vasomotion. Statins efficiently reduce plasma 
LDL cholesterol, an effect that may account for their benefi-
cial effect on endothelial function, but they also reduce cellu-
lar levels of isoprenoid compounds relevant for the bioavail-
ability of NO. Statins restore NO production by several 
mechanisms, including up-regulation of eNOS mRNA and 
protein levels and preservation of NO inactivation by reac-
tive oxygen species. These effects are mediated, at least in a 
part, through mechanisms independent of their lipid lowering 
effect (pleiotropic effects). The relevance of endothelium-
dependent effects on the early and delayed clinical benefit of 
statins, as well as the multiple ways by which statins may 
restore endothelial function acting not only on the endothe-
lium but also on endothelial progenitor cells, which probably 
could contribute to both ischemia-induced neovasculariza-
tion and endothelial regeneration after injury [62].  
  Patients with peripheral vascular disease are less likely to 
receive optimal medical management than patients with 
coronary artery disease. However, early medical treatment is 
critical because it is profoundly beneficial and the benefits 
are maximized. Even in patients with advanced disease re-
quiring invasive intervention, medical management has been 
proven to improve outcome, prolong the success of the inter-
vention, improve functional capacity, and prolong life. The 
vascular surgeon should be knowledgeable enough to initiate 
basic medical therapy and to define for their patients the 
goals that need to be met to optimize their medical manage-
ment. The vascular surgeon should be instrumental in assur-
ing that the peripheral vascular patient receives medical ther-
apy of the same standard as the patient with coronary dis-
ease. The major modifiable risk factors in the vascular pa-
tient are: smoking, high blood pressure, hyperlipidemia, 
physical inactivity, obesity, and diabetes. In addition, the use 
of beta blockers for patients with coronary disease and anti-
platelet therapy as well as angiotensin-converting enzyme 
(ACE) inhibitors are recommended for all patients with pe-
ripheral vascular disease. Statins have favourable effects on 
multiple interrelated aspects of vascular biology important in 
atherosclerosis. In particular they have beneficial effects on 
inflammation, plaque stabilization, endothelial dysfunction, 
and thrombosis. Statins have also been shown to be benefi-
cial in acute vascular events. ACE inhibitors have been 
shown to reduce cardiovascular morbidity and mortality in 
patients with peripheral arterial disease regardless of the 
presence or absence of hypertension. A number of the plei-
otropic effects of statins are shared by ACE inhibitors. The 
patients with known vascular disease should be treated ag-
gressively with a combination of a HMG CoA reductase 
inhibitor, an angiotensin-converting enzyme inhibitor, an 
antiplatelet agent and a beta blocker if there is a history of 
coronary disease. They should also receive tight control of 
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encouraged to stop smoking and should be provided with 
pharmaceutical and emotional support by their physicians. 
All of these patients should have their body mass index as 
close to normal as possible and be on a therapeutic lifestyle 
diet. Regular aerobic exercise is also indicated. Patients with 
symptomatic claudication should be considered for cilosta-
zol. Patients with multiple risk factors for vascular disease, 
but who do not have documented disease should also be on 
statin therapy. As more studies define the linear relationship 
between lower LDL-C levels and lowered risk of vascular 
events, indicating that the lower the LDL-C level, the lower 
the risk, experts are advocating more aggressive lipid-
lowering therapy. In patients with peripheral arterial disease, 
some experts now advocate lowering the goal of LDL ther-
apy to 70 mg/dL [63].  
  Spondyloarthritides are associated with increased cardio-
vascular risks, which can only partly be explained by tradi-
tional risk factors. It is likely that the chronic inflammatory 
state is involved. Cardiac pathologies in spondyloarthritides 
are conduction disturbances and valvular heart diseases. Re-
cent studies have highlighted that the chronic, systemic in-
flammatory condition of patients with spondyloarthritides 
may be involved in the development of cardiac and vascular 
pathologies [64]. Recent data have also focused on vascular 
pathologies and showed impaired endothelial function, sug-
gesting that atherosclerotic alterations could also be involved 
in increased cardiovascular mortality.  
DRUG ABUSE  
 Drugs
  of abuse, including cocaine, amphetamines, and 
heroin, have
 been associated with an increased risk of VD 
(65); drugs of abuse increased
  the risk of stroke 6.5-fold 
(95% CI 3.1 to 13.6) across all
 age groups and with an RR of 
11.2 (95% CI 3.2 to 42.5) in persons
 <35 years of age [66].  
  Drug addiction is often a chronic relapsing disorder asso-
ciated
 with a number of societal and health-related problems 
[67]. These drugs
 can cause abrupt changes in blood pres-
sure, induce vasculitic-type
  changes, lead to embolization 
caused by infective endocarditis
 and induce hemostatic and 
hematologic abnormalities that can
 result in increased blood 
viscosity and platelet aggregation [1]. Information about 
stroke-related drug abuse is mainly limited
 to epidemiologi-
cal studies focused on urban populations. An
 increase in the 
risk of both ischemic and hemorrhagic stroke
 has been re-
ported [68]. In one study, drug abuse increased
 the risk of 
stroke 6.5-fold (95% CI 3.1 to 13.6) across all
 age groups 
and with an RR of 11.2 (95% CI 3.2 to 42.5) in persons
 <35 
years of age. Long-term treatment strategies based
 on medi-
cation, psychological support, and outreach programs
 play an 
important part in treatment of drug dependency [69].  
  Drug abuse is associated with a variety of neurological 
complications. The use of certain recreational drugs shows a 
marked temporal association with the onset of both haemor-
rhagic and ischemic strokes, the majority of which develop 
within minutes to one hour after the administration of the 
index drug. Delayed onset of stroke has also been observed. 
Acute, severe elevation of blood pressure, cardiac dysrhyth-
mias, cerebral vasospasm, vasculitis, embolization due to 
infective endocarditis or dilated cardiomyopathy, emboliza-
tion due to foreign material injected with the diluents under 
non-sterile conditions and 'street drug' contaminants with 
cardiovascular effects have been suggested as possible un-
derlying mechanisms. Rupture of aneurysms and arte-
riovenous malformations have been detected in up to half of 
the patients with haemorrhagic stroke due to cocaine abuse. 
The less common findings reported have included a mycotic 
cerebrovascular aneurysm in a patient with infective endo-
carditis and haemorrhagic stroke. In addition to stroke, co-
caine seems to provoke vascular headache. Seizures precipi-
tated by recreational drug abuse are usually caused by acute 
intoxication in contrast to the withdrawal seizures encoun-
tered in subjects with alcohol abuse. Movement disorders 
and cerebral atrophy correlating with the duration of abuse 
have been described. Snorting of organic solvents may cause 
encephalopathy. Cases of spongiform leukoencephalopathy 
in heroin addicts have also been reported. Peripheral neu-
ropathy is occasionally precipitated by drug poisoning after 
intravenous administration. Impurities of the drug, risky ad-
ministration techniques, and the use of mixtures of various 
drugs, frequently with simultaneous alcohol drinking, should 
be taken into account when assessing the background of the 
adverse event as well as the overall lifestyle of the addicted 
subjects [1].  
  Cannabinoid drugs exert their effects primarily through 
activation of cannabinoid CB1 and CB2 receptors. Both CB1 
and CB2 receptors have been implicated in a number of car-
diovascular processes, including vasodilation, cardiac protec-
tion, modulation of the baroreceptor reflex in the control of 
systolic blood pressure, and inhibition of endothelial in-
flammation and the progress of atherosclerosis in a murine 
model. These effects are mainly mediated through central 
and peripheral nervous system CB1 receptors, vascular CB1 
receptors and immune cell CB2 receptors. Relevant cellular 
effects include: the inhibition of neurotransmitter release in 
the nucleus tractus solitarius and in peripheral adrenergic 
neurons; regulation of NOS activity in vascular beds; inhibi-
tion of vascular smooth muscle cell excitability; regulation 
of endothelial cell migration and proliferation; and effects on 
immune cell proliferation, activation, and inflammatory 
functions [70].  
  Several drugs of abuse have been associated with stroke.
 
However, there is a paucity of data on the independent risk
 of 
stroke associated with drugs of abuse and no controlled trials
 
demonstrating a reduction in risk with abstinence. Successful 
identification and management of drug abuse can be
  chal-
lenging. When a patient is identified as having a drug addic-
tion
  problem, referral for appropriate counselling may be 
considered.  
CONCLUSION  
  Experimental data, clinical investigations and epidemiol-
ogical studies identified the association of some pharmacol-
ogical treatment and the several drugs of abuse with VD. 
These findings highlight the need to carefully balance poten-
tial risk and benefits when considering pharmacological 
treatment in young and older people. The results of these 
findings represent a scientific and clinical necessity so as to 
identify a new group of “modifiable” risk factors to improve 
VD prevention. Further safety pharmacological studies 
should focus on identifying the pathophysiology mechanisms 
of vascular risk and determining whether and how different Clinical Pharmacology and Vascular Risk  The Open Neurology Journal, 2010, Volume 4    71 
regimens of pharmacological treatment and the abuse of sev-
eral drugs influence VD.  
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